# RAMP202 (NCT04620330)

> A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: avutometinib (VS-6766) plus defactinib; avutometinib (VS-6766)
- Indication: recurrent KRAS-mutant or BRAF-mutant non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04620330
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Verastem, Inc.
- Conditions: Non Small Cell Lung Cancer; KRAS Activating Mutation
- Interventions: avutometinib (VS-6766); avutometinib (VS-6766) and Defactinib
- Enrollment: 90
- Primary outcome: To determine the optimal regimen, either avutometinib (VS-6766) monotherapy or avutometinib (VS-6766) in combination with defactinib, in KRAS-G12V NSCLC
- Primary outcome: To evaluate the initial efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLC
- Primary outcome: To determine efficacy in KRAS-other (non-G12V) NSCLC
- Primary outcome: To determine the efficacy of avutometinib (VS-6766) in combination with defactinib in BRAF-MT NSCLC

## Indexed commentary on RAMP202 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=ramp202-nct04620330